The Efficacy of Baricitinib as a Treatment Option for Alopecia in Terms of Promoting Hair Regrowth and Improving Patient Reported Outcomes

    May 2024
    Bhaumik Patel, Abhiram Gollapudi, S Gollapudi, Srinidhi Banala, Brian Joseph Mathew, Prince Patel
    Image of study
    TLDR Baricitinib effectively promotes hair regrowth in severe alopecia with minimal side effects.
    Baricitinib, a Janus Kinase inhibitor, has demonstrated significant efficacy in promoting hair regrowth in patients with severe alopecia, as evidenced by improved Severity of Alopecia Tool (SALT) scores in the BRAVE-AA1 and BRAVE-AA2 trials. Patients treated with Baricitinib showed a marked improvement in SALT scores and a higher proportion achieved an absolute SALT score of ≤10 within 36 weeks compared to placebo, with minimal adverse effects reported. The FDA has approved Baricitinib for treating severe alopecia, but further research is needed to assess its long-term safety and confirm these findings in a larger cohort.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 11 results

    Related Research

    1 / 1 results